Geron Corp.

As of August 1, 2025, Geron Corp. shows a mildly bearish technical trend with mixed signals from MACD and RSI indicators, while significantly underperforming the S&P 500 with year-to-date returns of -62.71%.

As of August 8, 2024, Geron Corp. is rated as risky due to significant losses and negative return metrics, with key ratios indicating overvaluation compared to peers and a year-to-date stock performance of -62.71% versus the S&P 500's 12.22%.

As of August 8, 2024, Geron Corp. is considered overvalued with a "risky" valuation grade due to troubling financial ratios, including a Price to Book Value of 3.80, negative profitability metrics, and significant underperformance against the S&P 500, indicating a precarious market position compared to its peers.

As of May 22, 2025, the trend has shifted to mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish signals, despite a mildly bullish MACD on the weekly chart, while overall monthly indicators and underperformance against the S&P 500 reinforce the bearish outlook.

As of March 2022, the management team of Geron Corp. includes Dr. John Scarlett as Chairman, President, and CEO, with Ms. Karin Eastham as Lead Independent Director and independent directors Ms. Dawn Bir, Dr. V. Bryan Lawlis, Dr. Susan Molineaux, and Ms. Elizabeth O'Farrell.

Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing imetelstat for hematologic myeloid malignancies, with a market cap of approximately $923.53 million. As of March 2025, it reported net sales of $40 million and a net loss of $20 million.

As of Jun 18, Geron Corp. has a market capitalization of 923.53 million, with net sales of 116.29 million and a net profit of -139.02 million over the last four quarters.